|
|
Central neurocytoma: a review
Schmidt MH, Gottfried ON, von Koch CS, Chang SM, McDermott MW
Department of Neurological Surgery, University of Utah, Salt Lake
City, UT 84132, USA. meic.schmidt@hsc.utah.edu
Central neurocytomas are rare intraventricular neoplasms of the central nervous
system, compromising 0.25-0.5% of brain tumors.
The diagnosis and management of these tumors remains controversial since most
clinical series are small.
Typically, patients with central neurocytomas have a favorable prognosis, but in
some cases the clinical course is more aggressive.
Although histological features of anaplasia do not predict biologic behavior,
proliferation markers including MIB-1 might be more useful in predicting
relapse.
The most important therapeutic modality is surgery, and a safe maximal resection
confers the best long-term outcome.
In cases of a subtotal resection,'standard external beam radiation can be added
or radiation can be delayed until tumor progression occurs.
Smaller residual tumor volumes or recurrences can be treated with more conformal
radiation or focused radiosurgery.
Re-operation for recurrence should be considered if the procedure can be safely
performed.
Chemotherapy may be useful for recurrent central neurocytomas that cannot be
resected and have been radiated, although long-term responses have not been
reported for chemotherapy.
Overall, this paper reviews the findings of the larger studies and highlights
some of the important case reports that contribute to the current management of
central neurocytomas.
PMID: 15015671 [PubMed - indexed for MEDLINE]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15015671
|
